An oral BACE-1 inhibitor, verubecestat, that showed promising results in lowering Aβ levels in the CSF of rodents, non-human primates, and AD patients, was proven unsuccessful since it not only failed to improve cognition in patients with mild-to-moderate AD but also caused a series of adverse side effects [97]. The gene discussed is BACE1; the disease is Alzheimer disease.